Senores Pharmaceuticals IPO analysis

Senores Pharmaceuticals IPO (initial public offering) will open for subscription on December 20, 2024, and close on December 24, 2024. Here is a breakdown of the pharmaceutical company's strengths, weaknesses and growth prospects to help investors make an informed decision.

Senores Pharmaceuticals IPO in a nutshell

• Quality : Between FY22 and FY24, the company reported a three-year average ROE and ROCE of around 16.5 and 8.9 per cent, respectively.
  
• rowth : Between FY22 and FY24, its revenue and profit after tax grew by 289.1 and 474.5 per cent per annum.
  
• Valuation : At the upper end of the price band of Rs 391, the stock has a P/E and a P/B ratio of nearly 55.1 and 2.3 times, respectively.
  
• Overview: Senores Pharmaceuticals stands to take advantage of increasing expenditure and growing penetration of pharmaceuticals across the globe. Its presence in regulated and unregulated markets for off-patented generic products works in its favour. However, the lack of entry barriers and stiff competition in the generic drugs space can hurt its growth prospects.

About Senores Pharmaceuticals

Incorporated in 2017, Senores Pharmaceuticals primarily manufactures off-patent generic products and operates two manufacturing facilities in the US and India (Ahmedabad). It operates in over 45 countries, including the regulated markets of the US and Europe, which contributed to almost 61 per cent of its total revenue in H1 FY25.

Along with targeting the competitive generic drugs with a six-month exclusive sales right guarantee, Senores Pharmaceuticals has also partnered in sales agreements with companies like Sun Pharma, Dr Reddys, Alkem Laboratories, etc., to expand its product portfolio in the regulated markets. The company also does contract development for new drugs, which contributed to nearly 14 per cent of its revenue in H1 FY25.

Strengths of Senores Pharmaceuticals

• Long-term partnerships: Senores Pharmaceuticals boasts long-term sales partnerships with large, well-established players like Sun Pharma, Alkem, Jubilant, etc, along with manufacturing for big names in the US. Such partnerships with industry titans can help the company establish a significant presence across markets.

Weaknesses of Senores Pharmaceuticals

• Negative cash flows: Between FY22 and FY24, Senores Pharmaceuticals reported negative cash flow from operations. This was primarily due to higher working capital requirements as the company's operations scaled up significantly post the acquisition of Havix and Ratnatris.
  
• Regulatory issues: Senores Pharmaceuticals' US-based facility came under scrutiny from the US FDA in 2022, which cleared recently. Such regulatory actions can significantly impact its financials.

Risk report

Company and business

• Are earnings before tax of Senores Pharmaceuticals more than Rs 50 crore in the last 12 months?
  No. The company reported a profit before tax of Rs 24.9 crore in FY24.
  
• Will Senores Pharmaceuticals be able to scale up its business?
  Yes. Growing demand for healthcare products is expected to help the company scale up its business.
  
• Does Senores Pharmaceuticals have recognisable brands with client stickiness?
  No. The company operates in the generic medicines industry, which does not have client stickiness.
  
• Does the company have a credible moat?
  No. This is because Senores Pharmaceuticals operates in an industry with numerous organised players.

Management

• Do any of the company's founders still hold at least a 5 per cent stake? Or do promoters hold over a 25 per cent stake in the company?
  Yes. Senores Pharmaceuticals' promoters hold a 45.8 per cent stake in the company.
  
• Do the top three managers have over 15 years of combined leadership at Senores Pharmaceuticals?
  No. Senores Pharmaceuticals' top three managers, including its managing director (Swapnil Jatinbhai Shah), COO (Chetan Bipinchandra Shah) and CFO (Deval Rajnikant Shah), don't have a combined leadership experience of over 15 years.
  
• Is the management trustworthy? Is it transparent in its disclosures, which are consistent with SEBI guidelines?
  Yes. There is no information to suggest otherwise.
  
• Is the company's accounting policy stable?
  Yes. There is no information to suggest otherwise.
  
• Is Senores Pharmaceuticals free of promoter pledging of its shares?
  Yes. No shares have been pledged.

Financials

• Did the company generate a current and three-year average return on equity of over 15 per cent and a return on capital employed of over 18 per cent?
  No. Senores Pharmaceuticals' three-year average ROE and ROCE were 16.5 and 8.9 per cent, respectively. In FY24, it reported an ROE and ROCE of 26.2 and 10.6 per cent, respectively.
  
• Was the company's operating cash flow positive during the last three years?
  No. The company has reported negative cash flow from operations during FY22-24.
  
• Is the company's net debt-to-equity ratio less than one?
  Yes. Senores Pharmaceuticals had a net debt-to-equity of around 0.8 times as of September 2024.
  
• Is Senores Pharmaceuticals free from reliance on huge working capital for day-to-day affairs?
  No. The company's business is working capital intensive.
  
• Can the company run its business without relying on external funding in the next three years?
  No. Senores Pharmaceuticals will need to rely on external funding to meet its growth and working capital needs.
  
• Is Senores Pharmaceuticals free from meaningful contingent liabilities?
  No. As of Q2 FY25, the company's contingent liabilities and commitments as a percentage of total equity is over 50 per cent.

Valuations

• Does the stock offer an operating earnings yield of more than 8 per cent on its enterprise value?
  No. The stock offers an operating earnings yield of 1.5 per cent on its enterprise value.
  
• Is the stock's price-to-earnings (P/E) less than its peers' median level?
  No. Senores Pharmaceuticals' stock is valued at a P/E ratio of over 55 times compared to industry peers' median of 37.3 times.
  
• Is the stock's price-to-book (P/B) value less than its peers' average level?
  Yes. It is valued at a P/B ratio of over 2.3 times, compared to its industry peers' average of 5.5 times.

Assessing an IPO requires a careful evaluation of a company's strengths, weaknesses, and growth potential, just like we've outlined for Senores Pharmaceuticals. But wealth creation can only be achieved through a well-researched, balanced stock portfolio. Our Value Research Stock Advisor can help you with that. What do you get? Meticulously researched stock recommendations and ready-to-invest portfolios, updated every month.

Subscribe to Value Research Stock Advisor today and take charge of your financial future.

Disclaimer: This story is not a stock recommendation. Investors should do their due diligence before investing.

Also read: DAM Capital Advisors IPO: All you need to know